Cerecor Inc (NASDAQ:CERC): Steven Boyd’s Armistice Capital filed an amended 13D.
You can check out Armistice Capital’s latest holdings and filings here.
Please follow Armistice Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Armistice Capital or update its stock holdings.
Follow Steven Boyd's Armistice Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Armistice Capital | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
| Armistice Capital Master Fund, Ltd | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
| Steven Boyd | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
Follow Steven Boyd's Armistice Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.3)*
| Cerecor Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 15671L109 |
| (CUSIP Number) |
| Tohuan Steve Chen c/o Armistice Capital LLC 510 Madison Avenue 22nd Floor New York, NY 10022 Telephone Number: 212-231-4930 |
| (Name, Address and Telephone Number of Person Notices and Communications) |
| August 25, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
| If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_]. | |
| * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. | |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11
